dihydroergotamine mesylate injection / Generic mfg. - LARVOL DELTA

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Aspeya, Inc. | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • CNS Disorders • Migraine

Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Aspeya, Inc. | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Serotonin Receptor Signaling Promotes Amoeboid Migration of Melanoma Cells Through cAMP/PKA Activation. (PubMed, bioRxiv) - "Importantly, the FDA-approved migraine drug dihydroergotamine (DHE) blocks this pathway and significantly inhibits cancer cell motility. Supported by patient data linking reduced serotonin degradation with increased metastatic progression, these findings identify serotonin signaling as a novel driver of melanoma dissemination and provide a compelling rationale for repurposing serotonin-targeting therapeutics to prevent metastatic spread."

Journal • CNS Disorders • Melanoma • Migraine • Oncology • Pain • Solid Tumor

Multi-omics study of ABCA1 in sepsis: Integrating mendelian randomisation, single-cell transcriptomics, in silico knockout and virtual screening. (PubMed, Comput Biol Chem) - "ABCA1 is specifically expressed in CD16 + monocytes, and its perturbation affects lipid-related pathways. Virtual screening has identified potential drug candidates led by Dihydroergotamine (-12.2 kcal/mol). This study offers multi-level evidence supporting ABCA1 as a protective molecule and therapeutic target in sepsis."

Journal • Infectious Disease • Septic Shock • ABCA1

Drug interventions for acute treatment of pediatric migraine: a systematic review and network meta-analysis. (PubMed, Front Pharmacol) - "Sumatriptan/naproxen sodium, ibuprofen, zolmitriptan nasal spray, sumatriptan nasal spray, and rizatriptan showed statistical significance. Sumatriptan/naproxen sodium merits consideration, especially in patients exhibiting an inadequate response to monotherapy. Dihydroergotamine demonstrated potential benefits in refractory and chronic migraine; however, high-quality studies are warranted to validate these findings."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain • Pediatrics

An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects. (PubMed, J Clin Pharmacol) - "No clinically significant findings of a single dose of 5.2 mg STS101 alone or with itraconazole were observed on nasal examinations, safety laboratory values, vital signs, or safety electrocardiograms. In this study, no clinically meaningful drug-drug interactions were seen when STS101 was co-administered with a strong CYP3A4 inhibiting drug."

Clinical • Journal • PK/PD data • Cardiovascular • CNS Disorders • Migraine • Pain

Safety and Effectiveness of Pain Medications for Migraine Management During Pregnancy and Lactation. (PubMed, Paediatr Drugs) - "While very little safety data are available for new targeted migraine therapies such as calcitonin gene receptor protein (CGRP) blocking medications, including the CGRP monoclonal antibodies and gepants, well-established migraine therapies such as topiramate, valproate, and dihydroergotamine have known risk for teratogenicity. Likewise, the safety evidence for commonly used therapies for migraine in pregnancy such as propranolol and verapamil is of low quality, and the level of evidence for efficacy of verapamil is limited...The purpose of this review is to provide an overview of the available data on the safety of available and efficacious medications in the management of migraine during pregnancy and lactation. Based on more recent studies, there is increased evidence for use of more specific and efficacious medications for migraine, such as onabotulinumtoxinA, local nerve blocks with lidocaine, and triptans during pregnancy and lactation."

Journal • Review • CNS Disorders • Migraine • Pain

Dihydroergotamine alleviates circadian rhythm disorders through predicted interaction with to CRY1. (PubMed, Mol Divers) - "This integrated computational-experimental approach provides a robust framework for drug repurposing in circadian medicine, establishing DHE as a promising repurposing candidate for CRDs. Notably, the direct interaction between DHE and CRY1 remains a computational prediction that requires further experimental validation."

Journal • Cognitive Disorders • Sleep Disorder • CLOCK • CRY1 • PER1

Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Aspeya, Inc.

New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Multi-omics integration identifies cell-type-specific CISD1 and QDPR as druggable regulators linking hepatocellular carcinoma and major depressive disorder. (PubMed, Psychiatry Res) - "CISD1and QDPRconstitute genetically supported, druggable regulators that converge mechanistically on metabolic-inflammatory axes associated with HCC-MDD comorbidity. Repurposing dihydroergotamine warrants immediate preclinical evaluation for simultaneous oncologic and psychiatric benefits."

Journal • CNS Disorders • Depression • Hepatocellular Cancer • Major Depressive Disorder • Migraine • Mood Disorders • Oncology • Pain • Psychiatry • Solid Tumor • CD4 • CD8 • CISD1

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Aspeya, Inc.

New P2 trial • CNS Disorders • Migraine

The impact of ubrogepant on the use of other migraine acute treatments, opioid discontinuation, and healthcare utilization: Results from a pre-post opioid subcohort analysis (AHS 2026) - "Acute medications other than ubrogepant included acetaminophen, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, talbutal, barbital, codeine, hydrocodone, meperidine, morphine, oxycodone, propoxyphene, tramadol, aspirin, bromfenac, celecoxib, diclofenac, diflunisal, esomeprazole, etodolac, famotidine, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, lasmiditan, Zavegepant, and Rimegepant (<15 pills). Opioid use included acetaminophen/tramadol, oxymorphone, levorphanol, buprenorphine/naloxone, meperidine, morphine, oxycodone, codeine, methadone, oxycodone, hydromorphone, butorphanol, and tapentadol... In patients with a history of opioid use,..."

HEOR • CNS Disorders • Migraine • Pain

Efficacy and tolerability of IV dihydroergotamine in treating pediatric headache in the emergency department: A retrospective review (AHS 2026) - "Single-dose IV DHE is a safe, well-tolerated, and effective treatment option for pediatric patients with migraine refractory to standard therapy in the ED. In this cohort, 41% of DHE-treated patients were discharged from the ED with 1 in 5 achieving complete headache resolution. Patients who received DHE had a 72-h revisit rate (5%) comparable to the overall cohort (4%)."

Retrospective data • Review • CNS Disorders • Migraine • Mood Disorders • Pain

Migraine, tension-type headache and non-specific headache in children and adolescents with autism-spectrum disorder (AHS 2026) - "Cohorts were identified using ICD-9/10 codes for ASD and using migraine or headache-related ICD diagnoses from inpatient/outpatient claims, and pharmacy claims for migraine-specific medications (triptans, gepants, CGRP monoclonal antibodies, dihydroergotamine)... Headaches, including migraine, are highly prevalent among patients with autism. Disparities in diagnosis of migraine versus non-specific headache between primary language groups may suggest barriers to accurate diagnosis (limitations in communication due to autism and language barrier). Those with ASD and migraine have more comorbidities compared to those with ASD and non-specific headache or TTH."

Clinical • CNS Disorders • Epilepsy • Migraine • Musculoskeletal Pain • Pain

Methylergonavine: Alternative to repetitive dihydroergotamine for refractory migraine (AHS 2026) - "Methylergonavine may be a suitable alternative for carefully selected hospitalized individuals with refractory migraine whenever DHE is not available for use (Table 2)."

CNS Disorders • Migraine • Pain

Real-world Outcomes of GLP-1 Receptor Agonist Initiation in Migraine: A Propensity-matched Comparison with Topiramate (AHS 2026) - "Outcomes were assessed 1–365 days post-index, including healthcare utilization (emergency department visits, hospitalizations, and nerve blocks), treatment escalation via new oral acute or preventive prescriptions, and receipt of parenteral agents (ketorolac, dihydroergotamine, magnesium sulfate, antipsychotics), excluding individuals with prior use of each respective therapy. In this large, propensity-matched real-world cohort, GLP1RA initiation was associated with lower healthcare utilization and reduced treatment escalation compared with topiramate initiation. These patterns were observed across all outcomes evaluated during the 1–365-day post-index period. The findings reflect associations rather than treatment effects."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

Total Synthesis of 8-Hydroxy-dihydroergotamine, the Major Human Metabolite of Dihydroergotamine. (PubMed, Molecules) - "Both 8-hydroxy-dihydroergotamine and its 2H5-derivative were obtained as an equilibrating mixture of C-8 epimers (diastereomers), with the major isomer having (R)-configuration according to 1H NMR analysis. The syntheses described enable the routine synthesis of 50-100 mg quantities of each target molecule."

Journal • CNS Disorders • Migraine • Pain

Health Care Utilization in Refractory Migraine: A Cross-Sectional Analysis of a Cross-Institutional Electronic Health Care Records Database. (PubMed, Neurol Clin Pract) - "Higher health care utilization, greater comorbidity burden, and distinct geographic patterns are observed with increasing numbers of preventive medication trials in chronic migraine. These findings highlight the complexity of RM and underscore the need for earlier identification and more equitable access to comprehensive migraine care."

HEOR • Journal • Observational data • Retrospective data • Asthma • Cardiovascular • CNS Disorders • Depression • Epilepsy • Hypertension • Immunology • Migraine • Mood Disorders • Pain • Psychiatry • Pulmonary Disease • Respiratory Diseases

Status Migrainosus in Pediatric Populations: A Systematic Evidence Synthesis (AAN 2026) - "Dihydroergotamine was effective in many cohorts, but was associated with nausea/vomiting...Predictors such as comorbidities and age highlight the need for tailored prevention. Standardized pediatric-specific protocols and randomized, controlled trials to guide management are warranted."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Migraine • Mood Disorders • Pediatrics

Gene-guided repurposing identifies dihydroergotamine as a candidate inhibitor of the BCL2-SIVA1 axis in advanced gastric cancer in vitro. (PubMed, Biol Direct) - No abstract available

Journal • Preclinical • Gastric Cancer • Oncology • Solid Tumor • BCL2

DHE - past, present, and future: a narrative review. (PubMed, Pain Manag) - "Dihydroergotamine (DHE) was first approved in 1946 for the acute treatment of migraine...In addition, DHE has been investigated for potential repurposing of other indications. These too are described."

Journal • Review • CNS Disorders • Migraine • Pain

2025 New Drug Update (Part 2): Recent Approvals and Clinical Implications. (PubMed, Sr Care Pharm) - "This review synthesizes the latest evidence on recently approved medications including Atzumi™ and Brekiya® (dihydroergotamine mesylate) for migraine headaches, Attruby™ (acoramidis) for transthyretin amyloid cardiomyopathy, and Blujepa® (gepotidacin) for uncomplicated urinary tract infections. Insights are offered into prescribing considerations for these agents in older populations, potential drug-drug interactions, and administration and handling tips. This work will be of significant interest to health care professionals as they evaluate the appropriateness of these new therapeutic options."

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • CNS Disorders • Infectious Disease • Migraine • Nephrology • Pain

Functional characterization of angiogenesis genes in hepatocellular carcinoma via integrated bulk and single cell RNA sequencing. (PubMed, Sci Rep) - "Finally, molecular docking studies indicated that dihydroergotamine might be a promising candidate drug for targeting DAB2. This study systematically investigated the expression changes of angiogenesis genes in HCC, constructed a tumor prognosis prediction model, and explored potential therapeutic targets and drugs. These findings are of significance for guiding the selection of treatment options and identifying therapeutic targets for HCC."

IO biomarker • Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • APOA2 • THY1

Treating the Pain After the Cure: Therapeutic Approaches for Post-ECT Headache-A Systematic Review. (PubMed, J ECT) - "Treatments evaluated included sumatriptan, nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, propranolol, topiramate, valproic acid, mirtazapine, dihydroergotamine, topical salicylates, cryotherapy, and percutaneous electrical nerve stimulation. However, clinical phenotyping and a stepwise therapeutic approach may improve symptom control. This review provides a comprehensive summary of current options and offers guidance for individualized management of post-ECT headache."

Journal • CNS Disorders • Migraine • Musculoskeletal Pain • Pain

A dihydroergotamine autoinjector (Brekiya) for migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain